Opinion|Videos|October 9, 2024
Impact of Friedreich Ataxia on Quality of Life
Author(s)Sub Subramony, M.D.
Sub Subramony, M.D., discusses how the progression of patients' conditions often leads to a decline in quality of life and functional capabilities, highlighting key clinical indicators that necessitate the adoption of mobility aids.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Can you shed light on the trajectory of patients’ quality of life, functional capabilities, and overall well-being as the condition advances, and how do you typically discern indications in clinical settings that signal a decline in ambulation necessitating the adoption of mobility aids?
Advertisement
Related to this article
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5